SLC5A2 and type 2 diabetes mellitus: In January 2023, bexagliflozin became the fifth orally administered SGLT-2 inhibitor to be approved by the US Food and Drug Administration (FDA) for the treatment of T2D as an adjunct therapy to diet and exercise in the USA, following approval of dapagliflozin, canagliflozin, empagliflozin and ertugliflozin.19 The recommended dosage of bexagliflozin is 20 mg once daily in the morning, with or without food.